Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advocacy Is Central to Patient Care, Distinguished Lecturer Says

Thomas R. Collins  |  December 12, 2022

PHILADELPHIA—When she saw vaping taking hold at a middle school, heightening the risk of turning children into smokers as well as boosting the risk of rheumatic disease, Kamala Nola, PharmD, MS, went to work. Dr. Nola, associate dean of academic affairs at Lipscomb University, Nashville, called the Tennessee Pharmacists Association to express her concern.

“This is not good,” she told the association. Soon, she was speaking at a press conference on the topic alongside state legislators, who wanted to introduce legislative language on tobacco use, vaping and related comorbid conditions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“I went in and talked not just as a health professional, but as a mom and someone who cares for patients,” said Dr. Nola, recalling the occasion in a Distinguished Lecture at ACR Convergence 2022. “That passion came through, and it plays a role.”

In her talk, Dr. Nola emphasized that healthcare professionals should “play to your strengths” and speak out and take action on topics they feel strongly about. And she asked the audience to reconsider the concept of advocacy: It’s not just overt government-related activity, she stressed, but everyday actions as well.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We bring the role of an advocate with lots of differing strengths that we have,” she said. “It doesn’t have to be just a communicator, just a learner, an analytic person or an interconnector. Whatever those strengths are, they are all related to advocacy.

“The way we give drug information, the way we give instructions when they’re discharged from the hospital after knee replacement—those are advocacy pieces,” she said.

Fueling Advocacy with Collegiality

The culture of the medical field can act as a kind of advocacy fuel, she suggested. Attending the American Juvenile Arthritis Organization meeting in 1998 was a seminal moment for her, leading to lifelong relationships with mentors and others interested in advocacy.

“That conference changed my life,” she said. “As a result of that meeting, my husband and I made a decision as a family that we would always commit to working with those who have arthritis.”

Attending conferences still feeds into her advocacy mentality, she said.

“When I come to this meeting and when I go my Tennessee Pharmacists Association meetings or my national pharmacy meetings, I get revved, I get excited, because I’m with like-minded people,” she said. “Why is that? Part of it has to do with culture. We are here for a common reason.”

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceLegislation & AdvocacyMeeting Reports Tagged with:ACR Convergence 2022AdvocacyDr. Kamala Nola

Related Articles

    The 2021 ARP President’s Awards & Merit Awards

    November 14, 2021

    During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

    A Celebration of Accomplishments

    December 12, 2011

    ARHP recognizes health professionals for their contributions to the field

    Trump Nominates MD Anderson Oncologist as U.S. FDA Commissioner

    November 4, 2019

    (Reuters)—U.S. President Donald Trump has nominated Stephen Hahn, MD, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the U.S. Food and Drug Administration (FDA), the White House said on Friday. Dr. Hahn, a radiation oncologist who has been at MD Anderson in Houston since 2015, if confirmed would follow…

    What Should Providers Do to Address Polypharmacy?

    January 17, 2020

    ATLANTA—In a session at the 2019 ACR/ARP Annual Meeting, Susan Chrostowski, DNP, assistant clinical professor at Texas Woman’s University College of Nursing, Dallas, told the audience that she’d had a visit with a patient and asked how he was doing. “Not too good,” he said, explaining that his chest hurt. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUE“What’s…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences